You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Pulmonology

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.
Reynold A. Panettieri, Jr.
MD
Reynold A. Panettieri, Jr.

Learning objectives

  • Understand the role of type 2 cytokine-driven airway remodeling, and its association with poor clinical outcomes

Description

Reynold Panettieri, MD, discusses the role of type 2 inflammatory cytokines in the airway remodeling of severe asthma patients and the burden of associated clinical outcomes.

Tags
type 2 inflammationbarrier dysfunctioncytokineslung functionexacerbationsmucusIL-4IL-13airway remodeling
MAT-GLB-2407371 - 1.0 - 11/2024

About this expert

Pulmonology

Reynold A. Panettieri, Jr.

MD

Professor of Medicine and Vice Chancellor for Translational Medicine and Science | Rutgers University, New Jersey, United States

See author’s profile
Reynold A. Panettieri, Jr.

Related resources

How Can Biologics Improve Lung Function in Pediatric Severe Asthma?
Pulmonology
expert video

How Can Biologics Improve Lung Function in Pediatric Severe Asthma?

EAACI 2023 | Pediatric Severe Asthma: Why Lung Function Matters
Pulmonology
expert video

EAACI 2023 | Pediatric Severe Asthma: Why Lung Function Matters

Asthma White Board Video
Pulmonology
videoanimation

Asthma White Board Video

Type 2 Inflammation Underpins Pediatric Severe Asthma
Pulmonology
Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma Patients?
Pulmonology
expert video

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma Patients?

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age
Pulmonology
interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

Importance of Lung Function Assessment in Pediatric Asthma Patients
Pulmonology
videoanimation

Importance of Lung Function Assessment in Pediatric Asthma Patients

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission
Pulmonology
expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care
Pulmonology
expert video

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma
Pulmonology
Podcast

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Eosinophils as a Biomarker for Type 2 Asthma
Pulmonology
expert video

Eosinophils as a Biomarker for Type 2 Asthma

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13
Pulmonology
expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Type 2 Inflammation Digital Assessment Tool
Pulmonology
interactivity

Type 2 Inflammation Digital Assessment Tool

On-Treatment Asthma Remission: Moving Beyond Control
Pulmonology
interactivity

On-Treatment Asthma Remission: Moving Beyond Control

Expert Insights: Importance of Lung Function Assessment in Pediatric Asthma Patients
Pulmonology
expert video

Expert Insights: Importance of Lung Function Assessment in Pediatric Asthma Patients

FeNO as a Biomarker for Type 2 Asthma
Pulmonology
expert video

FeNO as a Biomarker for Type 2 Asthma

IgE as a Biomarker for Type 2 Asthma
Pulmonology
expert video

IgE as a Biomarker for Type 2 Asthma

Importance of Lung Function Assessment in Adult Asthma Patients
Pulmonology
videoanimation

Importance of Lung Function Assessment in Adult Asthma Patients

On-Treatment Clinical Remission in Asthma Patients Case Tool
Pulmonology
interactivity

On-Treatment Clinical Remission in Asthma Patients Case Tool

Pediatric Asthma Patient Case Tool: Ash
Pulmonology
interactivity

Pediatric Asthma Patient Case Tool: Ash

The Cycle of Inflammation in Adult Asthma
Pulmonology
interactivity

The Cycle of Inflammation in Adult Asthma

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients
Pulmonology
Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

Adult Asthma Interactive Patient Cases
Pulmonology
interactivity

Adult Asthma Interactive Patient Cases

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FranceChange country/region